Bristol-Myers shareholders approve $74 billion Celgene deal

Bristol-Myers Squibb shareholders approved the pharmaceutical giant’s $74 billion acquisition of cancer drugmaker Celgene in a vote on Friday.

Source link

Leave a Comment

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studiesGene-silencing: 'New class' of medicine reverses disease porphyria